CHICAGO—There are positive cancer trials, there are breakthrough cancer trials, and then there are trials like the one presented at the 2022 annual meeting of the American Society of Clinical Oncology that rewrite the rules of what is possible in oncology (abstract LBA5).
A phase 2 study of patients with early-stage rectal cancer, conducted at Memorial Sloan Kettering Cancer Center, has yielded never-before-seen results: complete remission in 100% of patients treated with neoadjuvant